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Abstract
Background: Human leukocyte antigens (HLAs) have been proposed to modulate the immune
response to Mycobacterium leprae. The association of HLA-DRB1 with leprosy has been reported
in several populations, but not in a Chinese population.
Methods:  The polymerase chain reaction-sequence-specific oligonucleotide probe with
Luminex100 (PCR-SSOP-Luminex) method was used to genotype HLA-DRB1 alleles in 305 leprosy
patients and 527 healthy control individuals.
Results: The HLA-DRB1*15 allele was significantly more prevalent among leprosy patients than
healthy controls, whereas the frequency of the HLA-DRB1*09 allele was lower among leprosy
patients, especially those with early-onset disease.
Conclusion: HLA-DRB1 alleles are associated with leprosy susceptibility in a Chinese population.
The HLA-DRB1*09 allele was found to be protective exclusively in a subset of early-onset leprosy
patients.
Background
Leprosy is a chronic infectious disease that occurs in
genetically predisposed individuals. It is caused by infec-
tion with the intracellular macrophage pathogen Mycobac-
terium leprae. Leprosy is characterized by a spectrum of
disease symptoms that result from interactions between
the host immune response and invading M. leprae. At the
lepromatous extreme, patients exhibit multibacillary
infection and an absence of antigen-specific cellular
immunity. At the tuberculoid extreme, patients exhibit
paucibacillary infection and a strong cellular immune
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response. Between these two extremes, borderline leprosy
patients show intermediate phenotypes [1].
Leprosy was once prevalent worldwide. However, there
has been a steady decline in the prevalence of leprosy
since the introduction of multidrug therapy by the World
Health Organization (WHO-MDT) in 1982 [2]. The detec-
tion rate of new cases, however, remains steady in some
countries, including several regions of China [3,4]. Since
2002, nearly 1,600 new cases have been detected annually
in China [4].
Previous studies have suggested a strong influence of
genetic factors in regulation of the anti-M. leprae immune
response [5,6]. Two recent genome-wide linkage analyses
have identified chromosome 6p21 as a major leprosy-sus-
ceptibility locus [7,8]. This region harbors the HLA gene
cluster, which has been extensively studied for its role in
leprosy pathogenesis [9-12]. In particular, HLA-DR alleles
have been consistently found to be associated with lep-
rosy [13]. Several studies reported an association of the
HLA-DR2 alleles HLA-DRB1*15, *16 *04, *10 and *12
with susceptibility or resistance to leprosy in Brazilian,
Vietnamese, South Indian, Indonesian, Thai and Argen-
tine populations [14-18]. In addition, HLA-DR3 alleles
were also found to be associated with leprosy susceptibil-
ity in Surinamese and Mexican populations [19,20]. These
studies have not only shown the importance of the HLA-
DR locus in leprosy susceptibility, but have also high-
lighted the fact that different HLA-DR alleles are associ-
ated with leprosy in different populations.
Although leprosy remains a major public health concern
and one of the infectious diseases most capable of causing
disability in China, the genetic susceptibility to leprosy in
Chinese populations has received little study. The only
such report was an investigation of the association of
HLA-DRB1 with leprosy in Southern China; however, due
to the small sample used, this study failed to detect this
well-established association [21]. In the current study, we
investigated the association of HLA-DRB1 with leprosy by
genotyping DRB1 alleles in a large Chinese Han sample of
305 leprosy patients and 527 healthy control individuals.
We further investigated the association of DRB1 alleles
with clinical subtype and age-of-onset of the disease.
Methods
Patients and controls
The study included 305 unrelated individuals with a diag-
nosis of leprosy and 527 control samples. The diagnosis of
leprosy was based on clinical assessment and detection of
acid-fast bacilli in skin-slit smears and histopathological
assessment of skin lesions. The patients were further clas-
sified as multibacillary (MB) or paucibacillary (PB) on the
basis of clinical and histological criteria [1]. The MB
patient subset (n = 179), which included patients with
lepromatous leprosy (LL), borderline lepromatous lep-
rosy (BL)and borderline (BB) leprosy, had a bacterial
index (BI) > 0. The PB group (n = 126) had a BI = 0, and
included patients with borderline tuberculoid leprosy
(BT) and tuberculoid leprosy (TT). Control sample
donors were recruited from the Shandong Blood Center.
Some characteristics of the 305 cases and 527 controls are
summarized in Table 1.
All subjects gave informed consent to participate in the
study. The protocol was approved by the Ethical Commit-
tee of the Shandong Provincial Institute of Dermatovener-
eology.
DNA extraction and HLA-DRB1* typing
Genomic DNA was extracted from peripheral blood using
a commercially available DNAzol extraction kit (E.Z.N.A
Blood DNA KIT, Omega Bio-tek, Inc).
The procedure for HLA genotyping by the polymerase
chain reaction-sequence-specific oligonucleotide probe
with Luminex100 (PCR-SSOP-Luminex) method
included PCR amplification, hybridization, a streptavi-
din-phycoerythrin (SA-PE) reaction, and analytical meas-
urements [22]. Target DNA was amplified by PCR using 5'
biotin-labeled primers that were highly specific to certain
sequences of HLA-DRB1 genes. PCR was carried out in a
20 μL reaction containing Lifecodes mixture (6 μL), Taq
polymerase (0.2 μL), nuclease-free water (11.8 μL) and
genomic DNA (3 μL). After denaturization, amplified
DNA was allowed to hybridize to complementary DNA
probes coupled to microbeads. The oligobead-coupled,
hybridized PCR product was labeled with streptavidin-
phycoerythrin. The fluorescent intensity of phycoerythrin
on each coded oligobead that had hybridized with the
Table 1: Characteristics of the study population of 305 cases and 527 controls
Population Sample size
(LL/BL/BB/BT/TT)
(MB/PB)
Male/Female Mean age Mean age onset
Case Chinese Han 305 278/27 67.5 19.0
(158/15/6/6/120)
(179/126)
Control Chinese Han 527 451/76 50.2 NA
NA: no onset age for controlsBMC Medical Genetics 2009, 10:133 http://www.biomedcentral.com/1471-2350/10/133
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biotin-labeled PCR product was measured using a
Luminex apparatus, and the HLA-DRB1* genotype was
determined with the assistance of Genosearch typing soft-
ware (Quick-Type for LifeMatch 2.0, Luminex Corpora-
tion). This HLA-typing analysis was done at the Shandong
blood center.
Statistical analysis
Power calculations, carried out using PS software http://
www.power-analysis.com/home.htm, showed that our
sample size of 305 patients and 527 controls had greater
than 95% power to detect an odds ratio (OR) of 2.0 at a
significance level of 5% when the frequency of the allele
of interest was greater than 0.10. Allele frequencies were
calculated by direct counting. The differences in allele fre-
quency between patients and controls and between early
onset and late-onset patients were tested using logistic
regression analyses with adjustments for age and gender.
The significance of the allele frequency difference between
the MB and PB cases was analyzed using Pearson Chi-
square tests. The nominal P-values were corrected for mul-
tiple testing (Pc-value) using the Bonferroni correction
(i.e., by multiplying the nominal P-values by the number
of HLA alleles being tested). A Pc-value < 0.05 was
accepted as statistically significant. The strength of associ-
ations was estimated by calculating ORs. Statistical analy-
ses were carried out using SPSS software (version 11.0).
Results
Table 2 summarizes the allele frequencies of HLA-DRB1*
alleles in the leprosy patient and control populations and
the results of association analyses. Of the 13 HLA-DRB1
alleles determined by the PCR-SSOP-Luminex method,
two alleles showed a significant difference in frequency (P
< 0.05) between patients and controls. The frequency of
the DRB1*15 allele among patients was 0.32 (195/610),
which was significantly higher than the frequency of 0.18
(185/1054) observed in the healthy controls (P < 0.001).
This difference remained significant after correcting for
multiple testing (Pc < 0.001). In contrast, the frequency of
the HLA-DRB1*09  allele was significantly lower in the
patient population than among controls (P = 0.002, Pc =
0.026).
We further investigated the association of HLA-DRB1*
alleles with the clinical subtypes of leprosy. No significant
differences in the allele frequencies were observed
between the MB and PB forms of the disease (Table 2). We
then investigated the association of HLA-DRB1* alleles
with early-onset (age-at-onset ≤ 16 years; n = 141) and
late-onset (age-at-onset > 16 years; n = 164) leprosy. Inter-
estingly, whereas the DRB1*15  allele was significantly
associated with both early- and late-onset leprosy, the
DRB1*09  was only significantly associated with early-
onset leprosy (Table 3).
All markers with allele frequency above 0.01 have been
tested and were in HW equilibrium.
Discussion
Leprosy is a chronic infectious disease caused by M. leprae.
The disease only occurs in a small percentage (1-3%) of
infected individuals [23], an observation that supports the
important role of host genetic factors in the development
of leprosy. The reported male-to-female patient ratio is
2:1 [24], consistent with the known role of gender as an
Table 2: Allele frequency distribution of HLA-DRB1* in patients versus controls, and MB versus PB forms of leprosy
Patients Controls MB PB
(n = 305) (n = 527) (n = 179) (n = 126)
Alleles 2 n AF 2 n AF P-value Pc-value AF AF P-value
HLA-DRB1*01 19 0.03 23 0.02 0.246 0.02 0.04 0.136
HLA-DRB1*03 14 0.02 40 0.04 0.520 0.04 0.02 0.224
HLA-DRB1*04 44 0.07 98 0.09 0.387 0.09 0.09 0.471
HLA-DRB1*07 73 0.12 164 0.16 0.427 0.16 0.13 0.197
HLA-DRB1*08 30 0.05 53 0.05 0.965 0.05 0.04 0.497
HLA-DRB1*09 49 0.08 140 0.13 0.002 0.026 0.13 0.07 0.06
HLA-DRB1*10 5 0.01 13 0.01 0.564 0.01 0.00 0.571
HLA-DRB1*11 43 0.07 76 0.07 0.585 0.07 0.06 0.188
HLA-DRB1*12 61 0.10 114 0.11 0.879 0.11 0.12 0.705
HLA-DRB1*13 29 0.05 63 0.06 0.058 0.06 0.04 0.232
HLA-DRB1*14 31 0.05 52 0.05 0.522 0.05 0.06 0.183
HLA-DRB1*15 195 0.32 185 0.18 < 0.001 < 0.001 0.18 0.29 0.991
HLA-DRB1*16 17 0.03 33 0.03 0.844 0.03 0.03 0.838
n, number of individuals; AF, allelic frequency.
P-values are from allele-based tests.BMC Medical Genetics 2009, 10:133 http://www.biomedcentral.com/1471-2350/10/133
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independent risk factor for leprosy susceptibility. In our
study, more male cases were collected than female cases;
thus, the observed association of the HLA-DRB1  allele
with leprosy was based on a mostly male population.
Many studies have reported an association of HLA-DR2
with leprosy, a linkage that is consistent with the finding
that HLA-DR antigens are associated with disease and the
suggestion that a majority of restriction determinants for
M. leprae reside on DR, and not DP or DQ molecules [25].
A functional study of Ag-specific T-cell responses within
the context of HLA-DR has shown that HLA-DR-associ-
ated immunity may be crucial in the adaptive immune
response to infection [26]. Thus, HLA-DR plays a major
role in the presentation of M. leprae antigens to T cells in
leprosy patients.
By analyzing a large number of Chinese leprosy patients,
our study has provided the first evidence for an associa-
tion of HLA-DRB1 with leprosy in a Chinese population
and provided additional support for the important role of
HLA in the pathogenesis of leprosy. HLA-DRB1*15 has
been demonstrated to be a leprosy-susceptibility allele
among Brazilian [14] and Indian [15] populations. In our
study, we found that HLA-DRB1*15 was also associated
with an increased risk of leprosy in a Chinese population,
and exhibited an allele frequency (32%) similar to that
observed in Indian populations (31%) but higher than
that observed among Brazilians (15%). The HLA-
DRB1*09 allele was found to be associated with protec-
tion against leprosy in our study; its frequency was signif-
icantly lower in leprosy patients than in controls, and the
association remained significant after correcting for mul-
tiple testing (P = 0.002, Pc = 0.026). This allele also
showed a protective effect against the disease in Southern
India, but the allele frequency among Indian patients was
0.017 [15], much lower than that observed in the Chinese
population studied here (0.08).
It has been reported that the HLA lymphotoxin-alpha
(LTA)+80 locus within the 6p21 chromosomal region is a
major risk factor for early-onset (i.e., < 16 years old) lep-
rosy [27]. To investigate whether the effect of HLA-DRB1*
on leprosy risk was age-onset dependent, we stratified lep-
rosy patients into early-onset (≤ 16 years) and late-onset
(> 16 years) groups in association analyses. Interestingly,
we found that HLA-DRB1*09 was associated with protec-
tion effect against early-onset leprosy (P = 0.003), but not
late-onset leprosy (P = 0.285). In contrast, the HLA-
DRB1*15 allele showed no age-onset-dependent effects.
To our knowledge, this is the first report that HLA-
DRB1*09 has an impact on disease onset. Further studies
will be needed to investigate the association of the
LTA+80 locus with leprosy in Chinese populations and
determine whether the association at the HLA-DRB1 locus
is independent of the LTA+80 locus.
De Vries et al. have proposed a two-step model for the
development of leprosy, proposing that successful infec-
tion of M. leprae is first established in genetically vulnera-
ble individuals, and subsequent clinical manifestation of
the disease is influenced by additional host and environ-
mental factors [28]. In our study, the frequencies of HLA-
DRB1  alleles were similar in the MB and PB patient
groups. This is consistent with the two-step model, sug-
gesting that the HLA-DRB1 locus may influence the over-
all susceptibility to leprosy per se. It has also been reported
that certain HLA-DRB1 alleles are associated with MB or
Table 3: Allele frequency distribution of HLA-DRB1* in early versus late-onset leprosy groups
Alleles Controls Early onset Late-onset
(n = 527) (n = 141) (n = 164)
AF AF P-value Pc-value AF P-value Pc-value
HLA-DRB1*01 0.02 0.03 0.924 0.04 0.162
HLA-DRB1*03 0.04 0.03 0.848 0.02 0.320
HLA-DRB1*04 0.09 0.09 0.685 0.06 0.406
HLA-DRB1*07 0.16 0.10 0.130 0.14 0.848
HLA-DRB1*08 0.05 0.05 0.926 0.05 0.723
HLA-DRB1*09 0.13 0.06 0.003 0.039 0.10 0.256
HLA-DRB1*10 0.01 0.003 0.168 0.01 0.285
HLA-DRB1*11 0.07 0.07 0.688 0.07 0.503
HLA-DRB1*12 0.11 0.11 0.480 0.09 0.324
HLA-DRB1*13 0.06 0.04 0.017 0.221 0.05 0.429
HLA-DRB1*14 0.05 0.05 0.607 0.05 0.988
HLA-DRB1*15 0.18 0.35 < 0.001  < 0.001 0.29 < 0.001 < 0.001
HLA-DRB1*16 0.03 0.03 0.758 0.02 0.495
n, number of individuals; AF, allelic frequency.
P-values are from allele-based tests.BMC Medical Genetics 2009, 10:133 http://www.biomedcentral.com/1471-2350/10/133
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PB forms of leprosy [29-31], suggesting that HLA-DRB1
may also be involved in the clinical manifestation of the
disease.
Taken together, our association analysis of stratified
patient groups indicates that the HLA-DRB1  locus is
largely associated with leprosy per se, and only HLA-
DRB1*09 shows an age-onset-dependent effect.
Conclusion
In summary, by analyzing a large sample of Chinese Han
leprosy patients, our genetic association study of the HLA-
DRB1 locus provides strong evidence for an association of
HLA-DRB1*15, as a susceptibility allele, and DRB1*09, as
a protective allele, with leprosy in a Chinese population.
Furthermore, we demonstrate for the first time that HLA-
DRB1*09 has an impact on the onset of disease, exerting
a protective effect only against early-onset leprosy. These
alleles could act alone or in combination with other genes
to confer susceptibility or resistance to leprosy in Chinese
Han populations.
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